264 related articles for article (PubMed ID: 33827469)
21. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
[TBL] [Abstract][Full Text] [Related]
22. Frequency of germline genetic variants in women with a personal or family history of breast cancer from Brazil.
Pereira JZ; Carneiro JG; Vieira MS; Valente BM; de Oliveira PZ; Mello CL; de Campos CLV; Gomes KB
Mol Biol Rep; 2022 Oct; 49(10):9509-9520. PubMed ID: 35980532
[TBL] [Abstract][Full Text] [Related]
23. Investigating the prevalence of pathogenic variants in Saudi Arabian patients with familial cancer using a multigene next generation sequencing panel.
AlHarbi M; Mobark NA; AlJabarat WAR; ElBardis H; AlSolme E; Hamdan AB; AlFakeeh AH; AlMushawah F; AlHarthi F; AlSharm AA; Balbaid AAO; AlJohani N; Zhou AY; Robinson HA; Alqahtani SA; Abedalthagafi M
Oncotarget; 2023 Jun; 14():580-594. PubMed ID: 37306523
[TBL] [Abstract][Full Text] [Related]
24. A comprehensive custom panel evaluation for routine hereditary cancer testing: improving the yield of germline mutation detection.
Velázquez C; Lastra E; Avila Cobos F; Abella L; de la Cruz V; Hernando BA; Hernández L; Martínez N; Infante M; Durán M
J Transl Med; 2020 Jun; 18(1):232. PubMed ID: 32522261
[TBL] [Abstract][Full Text] [Related]
25. Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma.
Mirabello L; Zhu B; Koster R; Karlins E; Dean M; Yeager M; Gianferante M; Spector LG; Morton LM; Karyadi D; Robison LL; Armstrong GT; Bhatia S; Song L; Pankratz N; Pinheiro M; Gastier-Foster JM; Gorlick R; de Toledo SRC; Petrilli AS; Patino-Garcia A; Lecanda F; Gutierrez-Jimeno M; Serra M; Hattinger C; Picci P; Scotlandi K; Flanagan AM; Tirabosco R; Amary MF; Kurucu N; Ilhan IE; Ballinger ML; Thomas DM; Barkauskas DA; Mejia-Baltodano G; Valverde P; Hicks BD; Zhu B; Wang M; Hutchinson AA; Tucker M; Sampson J; Landi MT; Freedman ND; Gapstur S; Carter B; Hoover RN; Chanock SJ; Savage SA
JAMA Oncol; 2020 May; 6(5):724-734. PubMed ID: 32191290
[TBL] [Abstract][Full Text] [Related]
26. Identification of hereditary breast and ovarian cancer germline variants in Granada (Spain): NGS perspective.
Molina-Zayas M; Garrido-Navas C; García-Puche JL; Barwell J; Pedrinaci S; Atienza MM; García-Linares S; de Haro-Muñoz T; Lorente JA; Serrano MJ; Poyatos-Andújar A
Mol Genet Genomics; 2022 May; 297(3):859-871. PubMed ID: 35451682
[TBL] [Abstract][Full Text] [Related]
27. Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients.
Rodríguez-Balada M; Roig B; Melé M; Albacar C; Serrano S; Salvat M; Querol M; Borràs J; Martorell L; Gumà J
Clin Biochem; 2020 Feb; 76():17-23. PubMed ID: 31786208
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of hereditary/familial breast cancer patients with multigene targeted next generation sequencing panel and MLPA analysis in Turkey.
Bora E; Caglayan AO; Koc A; Cankaya T; Ozkalayci H; Kocabey M; Kemer D; Aksoy S; Alicikus ZA; Akin IB; Durak MG; Gurel D; Yavuzsen T; Sevinc A; Somali I; Gorken I; Balci P; Karaoglu A; Saydam S; Ulgenalp A
Cancer Genet; 2022 Apr; 262-263():118-133. PubMed ID: 35220195
[TBL] [Abstract][Full Text] [Related]
29. Germline variants of uncertain significance, their frequency, and clinico-pathological features in a cohort of Sri Lankan patients with hereditary breast cancer.
Gunawardena K; Sirisena ND; Anandagoda G; Neththikumara N; Dissanayake VHW
BMC Res Notes; 2023 Jun; 16(1):95. PubMed ID: 37277882
[TBL] [Abstract][Full Text] [Related]
30. Elucidating the molecular basis of MSH2-deficient tumors by combined germline and somatic analysis.
Vargas-Parra GM; González-Acosta M; Thompson BA; Gómez C; Fernández A; Dámaso E; Pons T; Morak M; Del Valle J; Iglesias S; Velasco À; Solanes A; Sanjuan X; Padilla N; de la Cruz X; Valencia A; Holinski-Feder E; Brunet J; Feliubadaló L; Lázaro C; Navarro M; Pineda M; Capellá G
Int J Cancer; 2017 Oct; 141(7):1365-1380. PubMed ID: 28577310
[TBL] [Abstract][Full Text] [Related]
31. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
32. Next-generation sequencing for genetic testing of familial colorectal cancer syndromes.
Simbolo M; Mafficini A; Agostini M; Pedrazzani C; Bedin C; Urso ED; Nitti D; Turri G; Scardoni M; Fassan M; Scarpa A
Hered Cancer Clin Pract; 2015; 13(1):18. PubMed ID: 26300997
[TBL] [Abstract][Full Text] [Related]
33. Increased Risk of Hereditary Prostate Cancer in Italian Families with Hereditary Breast and Ovarian Cancer Syndrome Harboring Mutations in
D'Elia G; Caliendo G; Tzioni MM; Albanese L; Passariello L; Molinari AM; Vietri MT
Genes (Basel); 2022 Sep; 13(10):. PubMed ID: 36292577
[TBL] [Abstract][Full Text] [Related]
34. New germline mutations in BRCA1, ATM, MUTYH, and RAD51D genes in Tuvans early-onset breast cancer patients.
Gervas P; Molokov A; Ivanova A; Panferova Y; Kiselev A; Chernyshova A; Pisareva L; Choynzonov E; Cherdyntseva N
Exp Oncol; 2021 Mar; 43(1):52-55. PubMed ID: 33785725
[TBL] [Abstract][Full Text] [Related]
35. Genetic Characterization in High-Risk Individuals from a Low-Resource City of Peru.
Zavaleta E; Solis N; Palacios MI; Zevallos-Escobar LE; Corales EV; Bazo-Alvarez JC; Dominguez-Barrera C; Campos A; Wernhoff P; Ekstrøm PO; Møller P; Visnovska T; Hovig E; Balazar-Palacios J; Alvarez-Valenzuela K; Nakken S; Dominguez-Valentin M
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428697
[TBL] [Abstract][Full Text] [Related]
36. Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer.
Lin PH; Kuo WH; Huang AC; Lu YS; Lin CH; Kuo SH; Wang MY; Liu CY; Cheng FT; Yeh MH; Li HY; Yang YH; Hsu YH; Fan SC; Li LY; Yu SL; Chang KJ; Chen PL; Ni YH; Huang CS
Oncotarget; 2016 Feb; 7(7):8310-20. PubMed ID: 26824983
[TBL] [Abstract][Full Text] [Related]
37. Opportunistic testing of BRCA1, BRCA2 and mismatch repair genes improves the yield of phenotype driven hereditary cancer gene panels.
Feliubadaló L; López-Fernández A; Pineda M; Díez O; Del Valle J; Gutiérrez-Enríquez S; Teulé A; González S; Stjepanovic N; Salinas M; Capellá G; Brunet J; Lázaro C; Balmaña J;
Int J Cancer; 2019 Nov; 145(10):2682-2691. PubMed ID: 30927264
[TBL] [Abstract][Full Text] [Related]
38. Uncommon variants detected via hereditary cancer panel and suggestions for genetic counseling.
Özdemir Z; Çevik E; Öksüzoğlu ÖBÇ; Doğan M; Ateş Ö; Esin E; Bilgetekin İ; Demirci U; Köseoğlu Ç; Topal A; Karadurmuş N; Erdem HB; Bahsi T
Mutat Res; 2023; 827():111831. PubMed ID: 37453313
[TBL] [Abstract][Full Text] [Related]
39. Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity.
Penkert J; Schmidt G; Hofmann W; Schubert S; Schieck M; Auber B; Ripperger T; Hackmann K; Sturm M; Prokisch H; Hille-Betz U; Mark D; Illig T; Schlegelberger B; Steinemann D
Breast Cancer Res; 2018 Aug; 20(1):87. PubMed ID: 30086788
[TBL] [Abstract][Full Text] [Related]
40. Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019.
Kurian AW; Ward KC; Abrahamse P; Bondarenko I; Hamilton AS; Deapen D; Morrow M; Berek JS; Hofer TP; Katz SJ
J Clin Oncol; 2021 May; 39(15):1631-1640. PubMed ID: 33560870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
